The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Survey on manufacturing MSCs for the treatment of graft-versus-host disease
Mesenchymal stromal cells (MSCs) are multipotent progenitor cells that showed promising activity for the treatment of steroid-resistant acute graft-versus-host disease (SR aGvHD). Cristina Trento from King’s College London, London, UK, Maria Ester Bernardo from San Raffaele Telethon Institute for Gene Therapy (TIGET), San Raffaele Scientific Institute, Milan, Italy, and colleagues analyzed MSC manufacturing with a two-phase questionnaire across 17 European Society for Blood and Marrow Transplantation (EBMT) centers. Data was published in Biology of Blood and Marrow Transplantation.
More than 1500 MSC treatments have been performed in the 17 EBMT centers that were included in this study.
Key findings:
- MSCs were produced from bone marrow in 88% of cases, two centers manufactured MSCs from umbilical cord blood or cord tissue
- Manufacturing process: fetal bovine serum was replaced with human platelet lysate in several cases
- hPL (blood bank): 54%
- hPL (commercially available): 23%
- FBS: 23%
- 59% of centers used exclusively third-party MSCs, whilst one facility produced only autologous MSCs
- 71% of the centers used MSCs from frozen batches, 29% used fresh/frozen products
- Significant heterogeneity in product specification was found, most of the centers used CD19, CD34, CD14, HLA-DR and CD3 negativity, whereas fewer centers analyzed the expression of CD166, CD31 and CD44
In summary, this data indicates that there are inconsistent methods in MSC manufacturing and release criteria. The study group stated that there is a need for a mechanistic potency assay. “Until more informative potency assays become available, a more homogeneous approach to cell production may at least reduce variability in clinical trials and improve interpretation of results.”
References